Filter the latest scan's published facts — sector, size, yield, valuation — or rank them with a preset: cheapest, fastest growing, most profitable. Every view shows what is in the filings and prices; none ranks opportunity. The model behind the statuses showed no predictive power, and nothing here is a recommendation.
Scan of 2026-08-31 · 2,409 names scored · prices as of that date
Lowest valid-in-sector trailing valuation multiples today, latest scan: each name's sector percentiles on earnings yield, FCF yield, P/S, P/B, P/TBV and P/CFO, averaged (only the metrics valid in its sector — a REIT is never ranked by GAAP P/E here). “Cheapest” is a fact about trailing multiples versus sector peers, not a forecast that they re-rate.
Tested the unforgiving way: a composite ranking built from these same point-in-time filings (2017-01-31 to 2026-05-29) showed no measurable predictive power (mean IC 0.0168, t = 1.21), and its top quintile did not beat holding everything even before costs. Ranks like these describe today's record; they do not predict tomorrow's return.
284 names — page 5 of 6 · sector: Pharma & chemicals · Export CSV
| # | Ticker | Company | Sector | Cheap composite | P/E (trailing) | P/S (trailing) | FCF yield | Own 5y |
|---|---|---|---|---|---|---|---|---|
| 201 | KRYS | Krystal Biotech, Inc. Common Stock | Pharma & chemicals | 37.0 | 47.0× | 25.3× | 2.2% | +1.2σ |
Never the absolute multiple alone. A P/E of 9 is a fact; whether it is low depends on what you hold it against.
The five-year window is the empirically privileged one. Cheap against its sector and cheap against its own history are different claims, and a stock can be one without being the other — which is the whole reason both columns are shown rather than blended into a single score.
| 202 | CADL | Candel Therapeutics, Inc. Common Stock | Pharma & chemicals | 37.0 | — | — | -5.1% | +0.9σ |
| 203 | NTLA | Intellia Therapeutics, Inc | Pharma & chemicals | 37.0 | — | 23.2× | -23.7% | −0.4σ |
| 204 | ARTV | Artiva Biotherapeutics, Inc. Common Stock | Pharma & chemicals | 36.9 | — | — | -28.7% | — |
| 205 | NAMS | NewAmsterdam Pharma Company N.V. Ordinary Shares | Pharma & chemicals | 36.8 | — | 131× | -4.8% | — |
| 206 | SYRE | Spyre Therapeutics, Inc. Common Stock | Pharma & chemicals | 36.6 | — | — | -2.6% | +0.5σ |
| 207 | PTHS | Pelthos Therapeutics Inc. | Pharma & chemicals | 36.4 | — | 2.9× | -43.6% | — |
| 208 | EWTX | Edgewise Therapeutics, Inc. Common Stock | Pharma & chemicals | 36.1 | — | — | -3.3% | +1.1σ |
| 209 | SGMT | Sagimet Biosciences Inc. Series A Common Stock | Pharma & chemicals | 36.1 | — | 167×FY | -11.9% | — |
| 210 | CBIO | Crescent Biopharma, Inc. Common Stock | Pharma & chemicals | 36.0 | — | 38.5× | -15.4% | +0.9σ |
| 211 | STTK | Shattuck Labs, Inc. Common Stock | Pharma & chemicals | 35.9 | — | — | -7.8% | +1.1σ |
| 212 | DYN | Dyne Therapeutics, Inc. Common Stock | Pharma & chemicals | 35.7 | — | — | -10.6% | +0.8σ |
| 213 | IOVA | Iovance Biotherapeutics, Inc. Common Stock | Pharma & chemicals | 35.4 | — | 12.5× | -8.5% | +1.1σ |
| 214 | KYMR | Kymera Therapeutics, Inc. Common Stock | Pharma & chemicals | 35.2 | — | 190× | -2.5% | +0.9σ |
| 215 | SLS | SELLAS Life Sciences Group, Inc. Common Stock | Pharma & chemicals | 34.8 | — | — | -1.2% | +1.2σ |
| 216 | IMMX | Immix Biopharma, Inc. Common Stock | Pharma & chemicals | 34.6 | — | — | -4.4% | +1.4σ |
| 217 | VRDN | Viridian Therapeutics, Inc. Common Stock | Pharma & chemicals | 34.4 | — | 33.5× | -12.8% | +0.4σ |
| 218 | DERM | Journey Medical Corporation Common Stock | Pharma & chemicals | 34.4 | — | 3.2× | -10.7% | +0.3σ |
| 219 | OCUL | Ocular Therapeutix, Inc. | Pharma & chemicals | 34.2 | — | 44.1× | -10.5% | +0.5σ |
| 220 | IDXX | Idexx Laboratories Inc | Pharma & chemicals | 34.2 | 40.3× | 9.9× | 2.5% | +1.5σ |
| 221 | ALNY | Alnylam Pharmaceuticals, Inc. | Pharma & chemicals | 34.1 | 59.7× | 7.5× | 2.0% | +1.7σ |
| 222 | MRNA | Moderna, Inc. Common Stock | Pharma & chemicals | 33.9 | — | 25.0× | -2.9% | +0.1σ |
| 223 | ADPT | Adaptive Biotechnologies Corporation Common Stock | Pharma & chemicals | 33.7 | — | 13.5× | -0.7% | +1.4σ |
| 224 | ERAS | Erasca, Inc. Common Stock | Pharma & chemicals | 33.5 | — | — | -1.6% | +1.6σ |
| 225 | ARQT | Arcutis Biotherapeutics, Inc. Common Stock | Pharma & chemicals | 33.4 | — | 7.2× | 0.9% | +0.6σ |
| 226 | VERA | Vera Therapeutics, Inc. Class A Common Stock | Pharma & chemicals | 33.1 | — | — | -12.0% | −0.4σ |
| 227 | TWST | Twist Bioscience Corporation Common Stock | Pharma & chemicals | 32.9 | — | 21.1× | -1.0% | +0.9σ |
| 228 | NUVB | Nuvation Bio Inc. | Pharma & chemicals | 32.8 | — | 16.1× | -5.4% | +1.1σ |
| 229 | ARWR | Arrowhead Research Corporation | Pharma & chemicals | 32.8 | — | 18.6× | 2.8% | +1.0σ |
| 230 | AMLX | Amylyx Pharmaceuticals, Inc. Common Stock | Pharma & chemicals | 32.8 | — | — | -3.2% | +0.4σ |
| 231 | CLDX | Celldex Therapeutics, Inc | Pharma & chemicals | 32.5 | — | — | -8.6% | −0.5σ |
| 232 | STOK | Stoke Therapeutics, Inc. Common Stock | Pharma & chemicals | 32.4 | — | 60.5× | -7.6% | +0.2σ |
| 233 | MLTX | MoonLake Immunotherapeutics Class A Ordinary Shares | Pharma & chemicals | 32.3 | — | — | -20.6% | −2.1σ |
| 234 | MDGL | Madrigal Pharmaceuticals, Inc. Common Stock | Pharma & chemicals | 32.3 | — | 11.0× | -2.2% | +1.2σ |
| 235 | TVTX | Travere Therapeutics, Inc. Common Stock | Pharma & chemicals | 32.1 | — | 11.4× | 0.6% | +0.9σ |
| 236 | AURA | Aura Biosciences, Inc. Common Stock | Pharma & chemicals | 31.9 | — | — | -19.9% | −0.5σ |
| 237 | ETON | Eton Pharmaceutcials, Inc. Common Stock | Pharma & chemicals | 31.8 | — | 19.0× | 0.9% | +0.4σ |
| 238 | RLAY | Relay Therapeutics, Inc. Common Stock | Pharma & chemicals | 31.7 | — | 326× | -6.1% | +0.9σ |
| 239 | COGT | Cogent Biosciences, Inc. Common Stock | Pharma & chemicals | 31.6 | — | — | -4.8% | +1.3σ |
| 240 | IMVT | Immunovant, Inc. Common Stock | Pharma & chemicals | 31.3 | — | — | -4.9%FY | +0.9σ |
| 241 | PTGX | Protagonist Therapeutics, Inc | Pharma & chemicals | 31.2 | — | 128× | -1.2% | +0.5σ |
| 242 | ZURA | Zura Bio Limited Class A Ordinary Shares | Pharma & chemicals | 31.0 | — | — | -13.8% | −0.1σ |
| 243 | CORT | Corcept Therapeutics Inc. | Pharma & chemicals | 30.9 | 257× | 15.8× | 1.0% | −1.7σ |
| 244 | LLY | Eli Lilly & Co. | Pharma & chemicals | 30.9 | 41.1× | 14.4× | 2.0% | +0.2σ |
| 245 | TNGX | Tango Therapeutics, Inc. | Pharma & chemicals | 30.9 | — | 57.8× | -4.3% | +0.9σ |
| 246 | ACRS | Aclaris Therapeutics, Inc. | Pharma & chemicals | 30.5 | — | 101× | -6.2% | +0.6σ |
| 247 | SVRA | Savara Inc. | Pharma & chemicals | 30.2 | — | — | -9.7% | +0.8σ |
| 248 | CRNX | Crinetics Pharmaceuticals, Inc. | Pharma & chemicals | 30.1 | — | 495× | -4.7% | +1.3σ |
| 249 | UNCY | Unicycive Therapeutics, Inc. Common Stock | Pharma & chemicals | 29.6 | — | 194×FY | -21.8% | +1.0σ |
| 250 | DFTX | Definium Therapeutics, Inc. Common Shares | Pharma & chemicals | 29.5 | — | — | -3.5% | +1.1σ |
"Cheap composite" is a 0–100 position among valid sector peers — the mean of the component metrics' sector percentiles. "—" means the scan published no figure, deliberately. "n/a — masked" means the metric is misleading in that name's sector (a REIT's GAAP P/E, a bank's FCF yield) — hover for the reason, which comes from the same sector-validity rules the composite itself respects. An FY tag marks a trailing-year figure built from an annual filing; hover for what that means.